Livingston Group Asset Management CO operating as Southport Capital Management cut its holdings in Pfizer Inc. (NYSE:PFE) by 7.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 37,415 shares of the biopharmaceutical company’s stock after selling 3,109 shares during the quarter. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in Pfizer were worth $1,466,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Integrated Wealth Concepts LLC increased its stake in Pfizer by 14.2% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock valued at $2,840,000 after purchasing an additional 8,445 shares in the last quarter. Halsey Associates Inc. CT increased its position in shares of Pfizer by 73.8% in the 3rd quarter. Halsey Associates Inc. CT now owns 44,316 shares of the biopharmaceutical company’s stock valued at $1,592,000 after acquiring an additional 18,822 shares during the period. Whitnell & Co. increased its position in shares of Pfizer by 390.0% in the 3rd quarter. Whitnell & Co. now owns 50,507 shares of the biopharmaceutical company’s stock valued at $1,815,000 after acquiring an additional 40,200 shares during the period. IHT Wealth Management LLC raised its stake in Pfizer by 20.5% in the 3rd quarter. IHT Wealth Management LLC now owns 72,126 shares of the biopharmaceutical company’s stock worth $2,595,000 after acquiring an additional 12,291 shares during the last quarter. Finally, Altavista Wealth Management Inc. raised its stake in Pfizer by 7.3% in the 3rd quarter. Altavista Wealth Management Inc. now owns 116,631 shares of the biopharmaceutical company’s stock worth $4,191,000 after acquiring an additional 7,963 shares during the last quarter. Institutional investors own 70.21% of the company’s stock.

Shares of PFE stock traded down $0.37 on Thursday, hitting $40.46. The company had a trading volume of 419,454 shares, compared to its average volume of 16,200,954. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $44.56. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55. The firm has a market cap of $221.75 billion, a P/E ratio of 13.49, a price-to-earnings-growth ratio of 4.24 and a beta of 0.65. The company has a 50-day moving average price of $38.90 and a 200-day moving average price of $38.18.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.62 by $0.13. The firm had revenue of $12.68 billion for the quarter, compared to analyst estimates of $12.37 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. Pfizer’s revenue for the quarter was down 4.6% compared to the same quarter last year. During the same period last year, the company earned $0.78 earnings per share. Equities research analysts expect that Pfizer Inc. will post 2.97 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be issued a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a dividend yield of 3.76%. This is a positive change from Pfizer’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, January 30th. Pfizer’s payout ratio is 48.00%.

A number of analysts have commented on PFE shares. Royal Bank of Canada started coverage on Pfizer in a research report on Monday, January 6th. They set an “outperform” rating and a $46.00 price target for the company. Bank of America assumed coverage on Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price objective on the stock. JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. Credit Suisse Group reaffirmed a “hold” rating and set a $41.30 target price on shares of Pfizer in a report on Wednesday, November 6th. Finally, ValuEngine upgraded Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Nine equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and a consensus target price of $43.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: What Does a Sell-Side Analyst Rating Mean?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.